Key result
Atorvastatin reduces LDL-C by ~32% vs. placebo in pediatric type 1 diabetes.
RCT (n=42)
Double-blind
randomized
Answers are grounded in this paper and cite their sources.
Randomized trial assesses atorvastatin's impact on lipid profiles in children with type 1 diabetes, indicating potential cardiovascular benefits.
BACKGROUND: Children with type 1 diabetes (T1D) and elevated LDL-C have an increased risk for cardiovascular disease, a process that can begin in childhood. OBJECTIVE: To assess the safety and efficacy of atorvastatin improving lipid profiles in children with T1D and elevated LDL-C. SUBJECTS: Sixty children (31M/29F) with T1D, mean age: 15 ± 0.3 yr, mean diabetes duration: 6.8 ± 0.5 yr, HbA(1c) : 8.8 ± 0.2%, with mean LDL-C 124 ± 4.0mg/dl were recruited. METHODS: After a 3-month run-in period, subjects were randomized double-blindly to atorvastatin or placebo for 6 months. Lipoprotein subfractions were measured by ion mobility and glucose control by HbA1C; continuous glucose monitors were worn quarterly. RESULTS: After a run-in period, 42 subjects were randomized. There were decreases in total cholesterol (-21%), LDL-C (-32%), non-HDL-C (-31%) and apoB (-26%) in the atorvastatin group versus placebo (p < 0.001). Lipoprotein subparticles (LDL-large 1 and 2A, IDL-large and small, VLDL- medium and small) decreased with statins (p < 0.03 all). Insulin sensitivity scores remained constant in both groups and correlated inversely with apoB (r = -0.312 p = 0.039) and small LDL 3A (r = -0.404 p = 0.007). One subject had asymptomatic elevation of creatinine kinase which normalized after atorvastatin discontinuation. CONCLUSIONS: Atorvastatin lowered LDL-C, apoB, and atherogenic lipoprotein subparticles in children with T1D and elevated LDL-C without worsening insulin resistance. The drug was well tolerated and safe. Long-term studies would provide better insight on the impact of these interventions in the development of cardiovascular disease in children with diabetes.
No takes yet. Share an insight, caveat, or question.
Canas et al. (2014) conducted an RCT in Type 1 diabetes with elevated LDL-C (n=42). Atorvastatin vs. Placebo was evaluated on Decrease in LDL-C (p=<0.001). Atorvastatin decreased LDL-C by 32% versus placebo in children with type 1 diabetes and elevated LDL-C.
Synapse has enriched 10 related papers. Consider them for comparative context: